126353-32-0

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-1-pyrazin-2-yl-ethanone hydrobromide is used as a synthetic intermediate for the development of potent 6-heteroaryl-pyrrolidino-tetrahydroisoquinolines. These compounds exhibit dual histamine H3 antagonist/serotonin transporter inhibitor activity, which makes them promising candidates for the treatment of various central nervous system disorders, such as attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, and schizophrenia.
Additionally, due to its unique chemical structure, 2-bromo-1-pyrazin-2-yl-ethanone hydrobromide can be further modified and utilized in the synthesis of other bioactive molecules with potential applications in the pharmaceutical industry. Its versatility as a synthetic building block allows researchers to explore its use in creating novel drugs with improved efficacy and selectivity.

InChI:InChI=1/C6H5BrN2O.BrH/c7-3-6(10)5-4-8-1-2-9-5;/h1-2,4H,3H2;1H

Upstream product

• 22047-25-2 acetylpyrazine 

Downstream Products

• 1607432-27-8 N-[[1-(5-fluoro-4-methoxy-6-methyl-pyrimidin-2-yl)-4-(hydroxymethyl)-3-pyrazin-2-yl-pyrrolidin-3-yl]carbamothioyl]benzamide 
• 1607432-37-0 rac-N-[6-(5-fluoro-4-methoxy-6-methyl-pyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-yl]benzamide 
• 19847-11-1 2-amino-4-(pyrazin-2-yl)thiazole 
• 126353-30-8 N-[2-(4-Carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(pyrazin-2-yl)-morpholine 

Relevant academic research and scientific papers

BACE INHIBITORS

The present invention provides compounds of Formula I useful as BACE inhibitors in the treatment of e.g. Alzheimer's disease : wherein A is selected from the group consisting of; of; R1 is H or F; R2 is H, -OCH3, C1-C3 alkyl,; R3 is H, -CH3, or -OCH3; and R4 is H or F; or a pharmaceutically acceptable salt thereof.

Structure-activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis

A series of 2-aminothiazoles was synthesized based on a HTS scaffold from a whole-cell screen against Mycobacterium tuberculosis (Mtb). The SAR shows the central thiazole moiety and the 2-pyridyl moiety at C-4 of the thiazole are intolerant to modification. However, the N-2 position of the aminothiazole exhibits high flexibility and we successfully improved the antitubercular activity of the initial hit by more than 128-fold through introduction of substituted benzoyl groups at this position. N-(3-Chlorobenzoyl)-4-(2-pyridinyl) -1,3-thiazol-2-amine (55) emerged as one of the most promising analogues with a MIC of 0.024 μM or 0.008 μg/mL in 7H9 media and therapeutic index of nearly ～300. However, 55 is rapidly metabolized by human liver microsomes (t1/2 = 28 min) with metabolism occurring at the invariant aminothiazole moiety and Mtb develops spontaneous low-level resistance with a frequency of ～10-5.

ARYL SUBSTITUTED IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AS C3A RECEPTOR ANTAGONISTS

Aryl substituted imidazo[4,5-c] pyridine compounds of formula (I) or pharmaceutically acceptable salt thereof are provided. These compounds are useful in pharmaceutical compositions as C3a antagonists for treating a variety of medical conditions associated with the Complement cascade.

HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS

The present invention provides a compound of formula (I), which are useful as antiviral agents, in particular, as agents against viruses of the herpes family.